TrialThe oncologist2018

Phase II Study to Evaluate the Efficacy and Safety of Rilotumumab and Bevacizumab in Subjects with Recurrent Malignant Glioma.

Mary Lou Affronti et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.